Zhang Keqing, Gao Yuhai, Lu Yunfei
Department of Neurology, Zhejiang Hospital, Hangzhou, Zhejiang, China.
Brain Center, Zhejiang Hospital, Hangzhou, Zhejiang, China.
Front Pharmacol. 2025 Sep 12;16:1655864. doi: 10.3389/fphar.2025.1655864. eCollection 2025.
Adverse effects of medical treatment (AEMT) pose a significant global health concern, yet prior studies have mostly focused on specific adverse events or single countries, leaving the long-term global epidemiological patterns insufficiently characterized. As healthcare utilization grows, it is crucial to comprehensively quantify the global, regional, and national burden of AEMT and to forecast future trends for effective resource allocation and quality improvement.
We utilized data from the Global Burden of Disease (GBD) study 2021. AEMT were defined based on GBD criteria, and incidence, prevalence, deaths, and disability-adjusted life years (DALYs) data were extracted. This study was stratified by age, gender, region and socio-demographic index (SDI), and estimated annual percentage change was used to assess the trends from 1990 to 2021. Based on SDI, we conducted health inequality analysis and used the Bayesian age-period-cohort model to predict the trend changes over the next 15 years.
Globally, there were 12,481,276 new cases of AEMT, with 122,330 deaths, resulting in 4,846,981 DALYs loss in 2021. The age-standardized incidence (ASIR) and prevalence rates (ASPR) worldwide were showing an upward trend, especially in high SDI regions. Both age-standardized mortality (ASMR) and DALYs rates (ASDR) showed a gradual decline during the study period, but they still carried a heavy burden in the low SDI regions (2021 ASDR: 3.71 [95% UI: 2.90 to 5.68] per 100,000 persons-year; 2021 ASR for DALYs: 150.37 [95% UI: 109.08 to 215.24] per 100,000 persons-year). Australasia demonstrated the highest ASIR and ASPR, while Western Sub-Saharan Africa showed the highest ASMR and ASDR. Health inequality analyses revealed that both absolute and relative inequalities of DALYs were narrowing. By 2036, it is forecast that ASIR will decrease to 72.33 (19.40-125.27) per 100,000 persons-year, and ASDR will decrease to 40.98 (21.52-60.43) per 100,000 persons-year.
This study provided a comprehensive global, regional, and national assessment of the burden and inequality of AEMT over the past three decades, coupled with forecasts to 2036. The findings revealed distinct epidemiological patterns across SDI levels and regions, filling an important knowledge gap and offering evidence to guide healthcare safety strategies, medical education, and surveillance systems to further reduce the burden of AEMT worldwide.
医疗治疗的不良反应(AEMT)是一个重大的全球健康问题,但先前的研究大多集中在特定的不良事件或单个国家,导致全球长期的流行病学模式特征描述不足。随着医疗保健利用率的提高,全面量化全球、区域和国家层面的AEMT负担,并预测未来趋势以实现有效的资源分配和质量改进至关重要。
我们使用了《2021年全球疾病负担(GBD)研究》的数据。根据GBD标准定义AEMT,并提取发病率、患病率、死亡人数和伤残调整生命年(DALY)数据。本研究按年龄、性别、地区和社会人口指数(SDI)进行分层,并使用年度百分比变化估计来评估1990年至2021年的趋势。基于SDI,我们进行了健康不平等分析,并使用贝叶斯年龄-时期-队列模型预测未来15年的趋势变化。
2021年,全球有12,481,276例AEMT新发病例,122,330例死亡,导致4,846,981个DALY损失。全球年龄标准化发病率(ASIR)和患病率(ASPR)呈上升趋势,特别是在高SDI地区。年龄标准化死亡率(ASMR)和DALY率(ASDR)在研究期间均呈逐渐下降趋势,但在低SDI地区仍负担沉重(2021年ASDR:每10万人年3.71 [95% UI:2.90至5.68];2021年DALY的ASR:每10万人年150.37 [95% UI:109.08至215.24])。澳大拉西亚的ASIR和ASPR最高,而撒哈拉以南非洲西部的ASMR和ASDR最高。健康不平等分析显示,DALY的绝对和相对不平等都在缩小。预计到2036年,ASIR将降至每10万人年72.33(19.40 - 125.27),ASDR将降至每10万人年40.98(21.52 - 60.43)。
本研究提供了过去三十年AEMT负担和不平等的全面全球、区域和国家评估,并预测了到2036年的情况。研究结果揭示了不同SDI水平和地区的独特流行病学模式,填补了重要的知识空白,并为指导医疗安全策略、医学教育和监测系统提供了证据,以进一步减轻全球AEMT的负担。